Patent · US Active

Antibodies for prevention and treatment of diseases caused by clostridium difficile

US9815889B2 · kind B2 · utility

2Cited by

0References

4Claims

0Family size

Assignee

Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

Peter H. Seeberger · Potsdam, DE
Christopher Martin · Berlin, DE
Felix Broecker · Berlin, DE
Chakkumkal Anish · The Hague, NL

Key dates

Filing date	Dec 10, 2015
Grant date	Nov 14, 2017
Priority date	—
Expiry date	Feb 14, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/505
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the Clostridium difficile glycopolymer PS-I: α-L-Rhap-(1→3)-β-D-Glcp-(1→4)-[α-L-Rhap-(1→3)]-α-D-Glcp-(1→2)-α-D-Glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by C. difficile. The present invention further pertains to a method of treating or preventing a disease caused by the pathogen Clostridium difficile, which comprises administering to a subject said antibody or a vaccine composition comprising said antibody.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.